Platinum cytotoxic drugs in the municipal wastewater and drinking water, a validation method and health risk assessment

References

• Barlow S, Renwick A, Kleiner J, et al. 2006. Risk assessment of substances that are both genotoxic and carcinogenic: Report of an international conference organized by EFSA and WHO with support of ILSI Europe. Food Chem Toxicol 44:1636–50
   PubMed Web of Science ®Google Scholar
• Benford D, Bolger PM, Carthew P, et al. 2010. Application of the margin of exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem Toxicol 48:S2–S24
   PubMed Web of Science ®Google Scholar
• Besse J-P, Latour J-F, and Garric J. 2012. Anticancer drugs in surface waters: What can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs? Environ Int 39:73–86
   PubMed Web of Science ®Google Scholar
• Booker V, Halsall C, Llewellyn N, et al. 2014. Prioritising anticancer drugs for environmental monitoring and risk assessment purposes. Sci Total Environ 473:159–70
   PubMed Web of Science ®Google Scholar
• Boxall AB, Rudd MA, Brooks BW, et al. 2012. Pharmaceuticals and personal care products in the environment: What are the big questions? Environ Health Perspect 120:1221
   PubMed Web of Science ®Google Scholar
• Cunningham VL, Binks SP, and Olson MJ. 2009. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul Toxicol Pharmacol 53:39–45
   PubMed Web of Science ®Google Scholar
• Dearfield KL, and Moore MM. 2005. Use of genetic toxicology information for risk assessment. Environ Mol Mutagen 46:236–45
   PubMed Web of Science ®Google Scholar
• Emea EG. 2006. CHMP. EWP Workshop: Slowing the Progression of Neurodegenerative Diseases: Medicinal Products (MP) Clinical Development. London
   Google Scholar
• Ferrando-Climent L, Rodriguez-Mozaz S, and Barceló D. 2014. Incidence of anticancer drugs in an aquatic urban system: From hospital effluents through urban wastewater to natural environment. Environ Pollut 193:216–23
   PubMed Web of Science ®Google Scholar
• Fong CW. 2016. Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect. Free Radic Biol Med 95:216–29
   PubMed Web of Science ®Google Scholar
• Fonseca T, Morais M, Rocha T, et al. 2017. Ecotoxicological assessment of the anticancer drug cisplatin in the polychaete Nereis diversicolor. Sci Total Environ 575:162–72
   PubMed Web of Science ®Google Scholar
• Gandy J. 2015. Water intake: Validity of population assessment and recommendations. Eur J Nutr 54:11–6
   PubMed Web of Science ®Google Scholar
• Houeto P, Carton A, Guerbet M, et al. 2012. Assessment of the health risks related to the presence of drug residues in water for human consumption: Application to carbamazepine. Regul Toxicol Pharmacol 62:41–8
   PubMed Web of Science ®Google Scholar
• Humans IWGOTEOCRT & Organization WH. 1987. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, World Health Organization
   Google Scholar
• Isidori M, Lavorgna M, Russo C, et al. 2016. Chemical and toxicological characterisation of anticancer drugs in hospital and municipal wastewaters from Slovenia and Spain. Environ Pollut 219:275–87
   PubMed Web of Science ®Google Scholar
• Johnson AC, Oldenkamp R, Dumont E, et al. 2013. Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5‐fluorouracil, and capecitabine throughout the sewage effluents and surface waters of europe. Environ Toxicol Chem 32:1954–61
   PubMed Web of Science ®Google Scholar
• Lenz K, Hann S, Koellensperger G, et al. 2005. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge. Sci Total Environ 345:141–52
   PubMed Web of Science ®Google Scholar
• Meeravali NN, Madhavi K, Manjusha R, et al. 2014. Sequential extraction of platinum, cisplatin and carboplatin from environmental samples and pre-concentration/separation using vesicular coacervative extraction and determination by continuum source ETAAS. Talanta 118:37–44
   PubMed Web of Science ®Google Scholar
• Negreira N, De Alda ML, and Barceló D. 2013. On-line solid phase extraction–liquid chromatography–tandem mass spectrometry for the determination of 17 cytostatics and metabolites in waste, surface and ground water samples. J Chromatogr A 1280:64–74
   PubMed Web of Science ®Google Scholar
• Negreira N, De Alda ML, and Barceló D. 2014. Cytostatic drugs and metabolites in municipal and hospital wastewaters in Spain: Filtration, occurrence, and environmental risk. S Total Environ 497:68–77
   PubMed Web of Science ®Google Scholar
• Nussbaumer S, Bonnabry P, Veuthey J-L, et al. 2011. Analysis of anticancer drugs: A review. Talanta 85:2265–89
   PubMed Web of Science ®Google Scholar
• Rowney NC, Johnson AC, and Williams RJ. 2009. Cytotoxic drugs in drinking water: A prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 28:2733–43
   PubMed Web of Science ®Google Scholar
• Stanard B, Dolan DG, Hanneman W, Legare M, et al. 2015. Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds. Regul Toxicol Pharmacol 72:602–9
   PubMed Web of Science ®Google Scholar
• Vyas N, Turner A, and Sewell G. 2014. Platinum-based anticancer drugs in waste waters of a major UK hospital and predicted concentrations in recipient surface waters. Sci Total Environ 493:324–9
   PubMed Web of Science ®Google Scholar
• Zizza CA, Ellison KJ, and Wernette CM. 2009. Total water intakes of community-living middle-old and oldest-old adults. J Gerontol Ser A: Biomed Sci Med Sci 64:481–6
   PubMed Web of Science ®Google Scholar